Through the science of genetic engineering, these defendants developed a cell-line from plaintiff's cells which is capable of producing pharmaceutical products of enormous therapeutic and commercial value. The Regents, Golde, and Quan patented the cell-line along with methods of producing many products therefrom. The market potential of products from plaintiff's cell-line was predicted to be approximately three billion dollars by 1990. Hundreds of thousands of dollars have already been paid under these agreements to the developers. Without informing plaintiff, and in pursuit of the research efforts, Golde and UCLA continued to monitor him and take tissue samples from him for almost seven years following the removal of his spleen.
Defendant argues that none of the three conditions have been met.